Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients

被引：0
|
作者：
Ninh M. La-Beck
Beth A. Zamboni
Alberto Gabizon
Hilary Schmeeda
Michael Amantea
Paola A. Gehrig
William C. Zamboni
机构：
[1] University of North Carolina at Chapel Hill,UNC Eshelman School of Pharmacy
[2] Texas Tech University Health Sciences Center,Center for Immunotherapeutic Research and Department of Pharmacy Practice, School of Pharmacy
[3] Carlow University,Department of Mathematics
[4] Shaare Zedek Medical Center and Hebrew University-School of Medicine,Department of Oncology
[5] Pfizer,Department of Clinical Pharmacology
[6] Inc.,Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, UNC School of Medicine
[7] University of North Carolina at Chapel Hill,Molecular Therapeutics, Lineberger Comprehensive Cancer Center
[8] University of North Carolina at Chapel Hill,Institute for Pharmacogenomics and Individualized Therapy
[9] University of North Carolina at Chapel Hill,Carolina Center of Cancer Nanotechnology Excellence
[10] University of North Carolina at Chapel Hill,Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy
[11] University of North Carolina at Chapel Hill,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2012年 / 69卷
关键词：
Doxil; Liposomal; Pharmacokinetics; Variability; Monocytes; Reticuloendothelial system; Doxorubicin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：43 / 50
页数：7
相关论文
共 50 条
  • [31] Trabectedin in combination with pegylated liposomal doxorubicin for patients with ovarian cancer
    Tavella, K.
    Villanucci, A.
    Vannini, L.
    Montelatici, S.
    Lavacchi, D.
    Boni, L.
    Tomcikova, D.
    Amunni, G.
    Mazzei, T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [32] Pegylated liposomal doxorubicin for myeloid neoplasms
    Zhang, Cheng
    Yao, Han
    Kong, Pei-Yang
    Liu, Yao
    Gao, Lei
    Gao, Li
    Ma, Ying-Ying
    Liu, Jun
    Tan, Xu
    Zhang, Xi
    ANTI-CANCER DRUGS, 2019, 30 (09) : 948 - 952
  • [33] Pegylated liposomal doxorubicin in ovarian cancer patients with renal compromise
    Basu, C. K.
    Mukhopadhyay, A.
    Pandey, R.
    Dey, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [34] Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer
    Minisini, Alessandro M.
    Andreetta, Claudia
    Fasola, Gianpiero
    Puglisi, Fabio
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (03) : 331 - 342
  • [35] Acquired resistance to pegylated liposomal doxorubicin
    Kai, Megumi
    Tanei, Tomonori
    Liu, Yan Ting
    Saito, Yuki
    Ferrari, Mauro
    Yokoi, Kenji
    CANCER RESEARCH, 2015, 75
  • [36] Pegylated liposomal doxorubicin: Tolerability and toxicity
    Goram, AL
    Richmond, PL
    PHARMACOTHERAPY, 2001, 21 (06): : 751 - 763
  • [37] Efficacy of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma
    Lind, Pehr A.
    Naucler, Gisela
    Holm, Agneta
    Gubanski, Michael
    Svensson, Christer
    ACTA ONCOLOGICA, 2007, 46 (02) : 230 - 233
  • [38] Use of pegylated liposomal doxorubicin in patients with lymphoma and contraindications for anthracyclines
    Balensiefer, B.
    Christofyllakis, B.
    Bewarder, Y.
    Kaddu-Mulindwa, D.
    Thurner, L.
    Bittenbring, J. T.
    Ahlgrimm, M.
    Bewarder, M.
    Boehm, M.
    Stilgenbauer, S.
    Christofyllakis, K.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 193 - 193
  • [39] Pegylated liposomal doxorubicin in ovarian cancer
    Green, Andrew E.
    Rose, Peter G.
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2006, 1 (03): : 229 - 239
  • [40] Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma
    Amantea, MA
    Forrest, A
    Northfelt, DW
    Mamelok, R
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (03) : 301 - 311
12345